ArticleBMC cancer2026
FDG-PET/CT based small volume accelerated immuno chemoradiotherapy in locally advanced NSCLC (PACCELIO) - a randomized, open-label, multicenter phase II trial protocol.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06102057 (PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
Who cites it
1 citing paper in PubMed.
- Prognostic Factors and Survival in Surgically Treated Stage III Non-Small Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study.Current oncology (Toronto, Ont.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStandard treatment for unresectable stage III non-small cell lung cancer (NSCLC) involves chemoradiation (CRT) followed by PD-L1 targeting immune checkpoint inhibition (IO). Integrating 18 F-fluorodeoxyglucose-positron emission tomography (FDG-PET)/CT into radiotherapy planning reduces toxicity, improves CRT outcomes, and potentially enhances immunotherapy response. Hypofractionated, accelerated CRT shortens treatment time, improves compliance, and may increase CRT completion rates, qualifying more patients for consolidative IO. METHODS/
designPACCELIO is a multinational, multicenter, randomized, phase II trial comparing the safety and efficacy of FDG-PET/CT based, volume-reduced, hypofractionated CRT with consolidation durvalumab to standard-volume, conventionally fractionated CRT with consolidation durvalumab in inoperable stage III NSCLC. One hundred and ten patients will be enrolled in Germany, Austria, and Switzerland, randomized 1:1, stratified by age, NSCLC stage, and site. The primary objective is to increase completion of CRT with successful transition to consolidation immunotherapy. Secondary outcomes include locoregional and distant tumor control rates, overall survival, safety, and health-related quality of life (HR-QoL). Exploratory outcomes involve prognostic immunomarkers and PET parameters. The primary endpoint of treatment completion will be analyzed using Fisher's Exact test, with safety and efficacy outcomes analyzed via Kaplan-Meier. DISCUSSION: The PACCELIO trial addresses a clinical need in stage III NSCLC by combining FDG-PET/CT based RT volume reduction with hypofractionated accelerated CRT and durvalumab immunotherapy. This approach aims to improve treatment completion, compliance, tumor control, and reduce toxicity. The trial will provide insights into the efficacy and safety of this combined treatment, potentially influencing future standards in stage III NSCLC treatment. Recruitment began in July 2024, with ongoing enrollment.
trial registrationClinicaltrials.gov identifier: NCT06102057 (Date of initial registration: 26th October 2023), https://clinicaltrials.gov/study/NCT06102057 .
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.